NRTI-sparing combination of darunavir/ritonavir and raltegravir not a good option for patients with high viral load
Herpes drugs and viral load: valaciclovir works better than aciclovir
Valaciclovir slows HIV disease progression in pregnant and breastfeeding women
New integrase inhibitor dolutegravir looks potent and well-tolerated
Another NRTI-sparing regimen does well in treatment-naive patients
New NNRTI lersivirine matches efavirenz in phase 2 study
Once-daily elvitegravir matches raltegravir
HIV treatment in primary infection: 48 week course modestly delays CD4 drop
Raltegravir combined with Kaletra associated with good preservation of bone density over 96 weeks
